Press Releases and News

Aphios Granted United States Patent for Oral Delivery of Cannabinoids such as Δ9-THC in Nanoparticles
November 04, 2013
Woburn, Mass. − Aphios Corporation today announced that it received notification of allowance for a United States Patent entitled "Nanoencapsulated Delta-9-Tetrahydrocannabinol" for the oral delivery of cannabinoids such as Δ9-THC in biodegradable polymer nanoparticles.

According to Dr. Trevor P. Castor, co-inventor of the technology, "The patented technology will be utilized in the manufacturing of APH-0812 for pain and cachexia in AIDS and cancer patients, and APH-1305 for Multiple Sclerosis and other CNS disorders. The nanotech formulation of Δ9-THC will also have applicability in several other chronic diseases such as obesity, smoking cessation and schizophrenia."

In the currently marketed oral formulation, synthetic Δ9-THC (Dronabinol®) is dissolved in sesame seed oil and is commercially available as an oral capsule (Marinol®). Oral administration causes slow, variable Δ9-THC uptake. In addition, it also requires drug administration several times a day because of first pass metabolism.

For the novel patented formulation, pharmaceutical grade Δ9-THC and other cannabinoids from Cannabis sativa with a >99% purity are first manufactured following cGMP utilizing Aphios' patented SFS-CXP manufacturing technology platform. Our scientists and engineers then utilize Aphios' patented SFS-PNS polymer nanospheres technology platform to encapsulate Δ9-THC in a biodegradable polymer. Nanoencapsulation protects Δ9-THC transport to the stomach, enhances its passage across the stomach lining of the gut and protects it from first pass metabolism in the liver. Nanoencapsulation slows the release of Δ9-THC, controlling the amount of drug in the bloodstream and reducing the frequency of drug administration during the day. Alternatively, the nanoformulation will be utilized to deliver Δ9-THC and other cannabinoids from a subcutaneously implanted depot.

Aphios® Corporation, Woburn, MA is a clinical stage biotechnology company developing green, enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, Aphios is developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and central nervous system disorders.

Research leading to these discoveries were supported by grants from the National Cancer Institute (NCI) and the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI, NIDA or NIH.


###